Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 32 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

47%

15 trials in Phase 3/4

Results Transparency

15%

4 of 27 completed with results

Key Signals

4 with results100% success

Data Visualizations

Phase Distribution

24Total
P 1 (5)
P 2 (4)
P 3 (10)
P 4 (5)

Trial Status

Completed27
Unknown2
Active Not Recruiting1
Withdrawn1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 27 completed trials

Clinical Trials (32)

Showing 20 of 20 trials
NCT06950645Phase 1CompletedPrimary

The Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

NCT06967272Phase 2RecruitingPrimary

PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells)

NCT06882070CompletedPrimary

ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage

NCT05621655Phase 2Active Not Recruiting

Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers

NCT04185545Phase 3CompletedPrimary

Efficacy, Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates

NCT05958771Phase 3UnknownPrimary

The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E

NCT04819412Phase 3CompletedPrimary

To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus

NCT04596696Phase 3CompletedPrimary

Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam

NCT01026779CompletedPrimary

Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island

NCT04116307Phase 4CompletedPrimary

Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis

NCT02062385Phase 3CompletedPrimary

Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)

NCT01600092Phase 3CompletedPrimary

A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)

NCT02584816Phase 3CompletedPrimary

Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization

NCT03474055Phase 2CompletedPrimary

Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India

NCT02133690Phase 3CompletedPrimary

A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants

NCT02728869Phase 1CompletedPrimary

Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants

NCT01236066CompletedPrimary

Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia

NCT01202201Completed

A Retrospective Survey of the Burden of Rotavirus Gastroenteritis (RV GE) and Nosocomial RV GE in Japan

NCT00169455Phase 3CompletedPrimary

Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants

NCT00953056Phase 1CompletedPrimary

A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)

Scroll to load more

Research Network

Activity Timeline